Replimune Group Inc (REPL): Next-Year EPS Estimate 33.89%
As of 2026-09-17, Replimune Group Inc (REPL) has a next-year EPS growth estimate of 33.89%. Featured in our EPS revision report on 2026-04-22.
On 2026-09-11, analyst consensus for REPL's next-year EPS growth shifted from 27.01% to 33.89% — a positive change of 6.88 percentage points. The revised estimate has been sustained across 6 subsequent trading sessions. Current-year growth is projected at 14.60%.
What's Driving This
The primary driver appears to be the EPS revision, with next-year growth estimates raised from 27.01% to 33.89% on 2026-09-11 and extending to a net +8.37 pp gain across two trading sessions, indicating continued momentum. No recent headline plausibly explains the move: coverage centers on an FDA complete response letter for RP1 in advanced melanoma, a sharp share price
Generated 2026-09-17 from news as of 2026-09-17
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 33.89%
- EPS growth this year
- 14.60%
- EPS next quarter (est)
- -$0.78
- Last price
- $12.87
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-09-17 | 33.89% | 14.60% | -$0.78 | $12.87 |
| 2026-09-16 | 33.89% | 14.60% | -$0.78 | $12.96 |
| 2026-09-15 | 33.89% | 14.60% | -$0.78 | $13.03 |
| 2026-09-14 | 33.89% | 14.60% | -$0.78 | $13.11 |
| 2026-09-13 | 33.89% | 14.60% | -$0.78 | $12.92 |
| 2026-09-11 | 33.89% | 14.60% | -$0.78 | $12.92 |
| 2026-09-10 | 27.01% | 16.77% | -$0.78 | $13.24 |
| 2026-09-09 | 27.01% | 16.77% | -$0.78 | $14.45 |
| 2026-09-08 | 27.01% | 16.77% | -$0.78 | $14.77 |
| 2026-09-07 | 27.01% | 16.77% | -$0.78 | $15.04 |
| 2026-09-06 | 25.52% | 18.01% | -$0.75 | $15.04 |
| 2026-09-04 | 25.52% | 18.01% | -$0.75 | $15.04 |
| 2026-09-03 | 25.52% | 18.01% | -$0.75 | $15.29 |
| 2026-09-02 | 25.52% | 18.01% | -$0.75 | $15.98 |
| 2026-09-01 | 25.52% | 18.01% | -$0.75 | $15.67 |
| 2026-08-31 | 25.52% | 18.01% | -$0.75 | $15.30 |
| 2026-08-30 | 25.52% | 18.01% | -$0.75 | $15.50 |
| 2026-08-29 | 25.52% | 18.01% | -$0.75 | $15.50 |
| 2026-08-28 | 25.52% | 18.01% | -$0.75 | $15.50 |
| 2026-08-27 | 25.52% | 18.01% | -$0.75 | $15.60 |
| 2026-08-26 | 25.52% | 18.01% | -$0.75 | $15.88 |
| 2026-08-25 | 29.89% | 15.30% | -$0.79 | $15.80 |
| 2026-08-24 | 29.89% | 15.30% | -$0.79 | $14.71 |
| 2026-08-23 | 29.89% | 15.30% | -$0.79 | $14.77 |
| 2026-08-21 | 29.89% | 15.30% | -$0.79 | $14.77 |
| 2026-08-20 | 29.89% | 15.30% | -$0.79 | $14.05 |
| 2026-08-16 | 25.51% | 13.02% | -$0.78 | $14.97 |
| 2026-08-14 | 31.58% | 15.83% | -$0.76 | $14.97 |
| 2026-08-13 | 31.21% | 18.00% | -$0.69 | $15.19 |
| 2026-08-12 | 31.21% | 18.00% | -$0.69 | $15.24 |
Reports Featuring REPL
Recent News
- Replimune Plans Layoffs After FDA Rejects Cancer Therapy Again. The Stock Craters 64%.Barrons.com
- Replimune melanoma therapy rejected by FDA, shares plungeProactive
- FDA issues complete response letter to Replimunes RP1 for melanomaPharmaceutical Technology
- Replimune sinks 57% on second FDA rejection of melanoma drug; stock downgradedInvesting.com
- Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced MelanomaGlobeNewswire
- Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced MelanomaGlobeNewswire
- Replimune Stock Tumbles After FDA Rejects Skin Cancer Therapy for Second TimeBarrons.com
- Replimune Stock Tumbles After FDA Rejects Skin Cancer Therapy for Second TimeBarrons.com
Screen Performance
Aggregate stats across all 2046 tickers our top-EPS-revision screen has flagged over the past 169 days.
- Median return since detection
- +0.4%
- % of tickers in the green
- 51%
- Median return on winners
- +21.4%
- Large revisions captured
- 1726
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Replimune Group Inc's next-year EPS growth estimate?▾
As of 2026-09-17, Replimune Group Inc (REPL) has a next-year EPS growth estimate of 33.89%, based on analyst consensus.
When was the latest EPS estimate revision for REPL?▾
The most recent revision occurred on 2026-09-11, when analysts adjusted the next-year EPS growth estimate from 27.01% to 33.89%.
What sector and industry does Replimune Group Inc belong to?▾
Replimune Group Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. REPL appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Replimune Group Inc (REPL) appears here because it was detected by our daily top-EPS-revision-performer screen.